Skip to main content
Premium Trial:

Request an Annual Quote

Common, But Mighty


A new study recently published in ACS Medicinal Chemistry Letters adds another dimension to aspirin, reports The Scientist's Bob Grant. Researchers at the City University of New York Medical School have designed four new forms of aspirin that release nitric oxide and hydrogen sulfide, Grant says. And these NOSH-Aspirins have the potential to slow tumor growth in colon, pancreatic, breast, lung, and prostate cancers, and leukemia, the researchers suggest. "Though regular aspirin and other nonsteroidal anti-inflammatory drugs have shown promise in curtailing tumor growth by knocking back inflammation, they come with nasty side effects such as the risks of gastrointestinal and brain bleeding and liver toxicity," Grant says. "The NOSH-Aspirins tested, on the other hand, did not seem to damage surrounding cells. Plus, one the new aspirins tested appeared to be more than 100,000 times more effective against cancer than normal aspirin."

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.